Our mission is to create products that deliver on significant unmet medical needs and through ground-breaking innovation and cutting-edge research we have developed a number of new technologies that will provide better patient outcomes.
Solvotrin’s R&D focus is on four therapeutic areas:
Active Iron Post Marketing Clinical Study;
Solvotrin has an active clinical development programme studying the efficacy and tolerability of Active Iron in people with an Intolerance to oral Iron. In collaboration with multinational partners, these studies will be continued and extended to include patient groups with anaemia of chronic disease, for example Chronic Kidney Disease. Ongoing research in the lab is helping to support these activities and is producing new insights into Active Iron’s favourable tolerability profile.
In collaboration with industry partners and scientists in Trinity College Dublin, Solvotrin is developing new applications of Active Iron Technology for food supplementation and fortification. These will be used, for example, in novel iron supplementation products for infants and children. We are also developing new presentations of Active Iron for use in special medical needs, for example in the management of patients with intestinal anatomical rearrangements (e.g. bariatric surgery) and for patients receiving enteral feeding.
Solvotrin scientists working in collaboration with immunologists in TCD have patented a family of novel compounds that selectively inhibit T-cell metabolism and proliferation. These substances show very promising effects in functional models of skin inflammation and in models of cutaneous T-cell lymphoma. The lead compound is broken down in skin to innocuous or already approved substances, de-risking late stage development in topical application. The compound properties make it very promising for the management of several serious skin diseases with high unmet need. Solvotrin is currently seeking scientific/business partners for a clinical dermatology programme for applications of the technology in skin cancers with orphan disease prevalence.
Solvotrin has a substantial patent portfolio in aspirin prodrugs and related compounds principally intended for management of cardiovascular disease. Some compounds in this portfolio may have applications in pain and in cancer chemoprevention, for example in high risk states such as colorectal metaplasia.